Curriculum in CardiologyRheumatoid arthritis and cardiovascular disease
Section snippets
Epidemiology of heart disease in RA
Patients with RA have a 1.5- to 2.0-fold increased risk of developing coronary artery disease (CAD) compared with the general population,1, 2 similar in magnitude to the risk imparted by diabetes mellitus.3 This increased CAD risk is evident even before the clinical recognition of RA: at diagnosis, individuals with RA were more than 3 times as likely to have had a prior myocardial infarction (MI) than subjects without RA.2 An expert committee of the European League Against Rheumatism has
Cardiovascular risk factor profile in RA
Patients with RA tend to have a different profile of cardiac risk factors, including a higher frequency of smoking and an altered lipid profile, compared with the general population. The lipid profile in RA is characterized by suppression of total and low-density lipoprotein (LDL) cholesterol levels during periods of high-grade inflammation, with a proportionately greater suppression of high-density lipoprotein (HDL) levels, yielding an unfavorable ratio of total to HDL cholesterol. Lipid
Heart disease management/outcome in RA
Patients with RA are typically managed by several physicians, and coordination of care may be suboptimal. Smoking cessation and control of standard risk factors are all indicated in patients with RA but may be underused because of the understandable focus on management of RA itself. Despite the well-understood benefits of exercise on general and CV health, most patients with RA do not pursue a regular exercise program.22, 23 Both aerobic exercise training and resistance exercise training for
Effect of RA therapies on CV risk in RA
Rheumatoid arthritis therapies target inflammation, a CV risk factor that is also important in patients without rheumatic disease. Understanding how these therapies also modify CV risk in RA may provide insight into the inflammatory component of CV risk for all patients.
Glucocorticoids have been widely used in RA to acutely control pain and inflammation associated with RA flares. However, the beneficial anti-inflammatory effects of glucocorticoids, which can improve mobility, are also
Effect of heart disease therapies in patients with RA
There have been relatively few patients with rheumatic diseases enrolled in major clinical trials of primary or secondary prevention. Although commonly used CV therapies are presumed to be effective in patients with RA, there is little direct evidence of their efficacy.
Statins (hydroxymethylglutaryl CoA reductase inhibitors) appear to reduce vascular inflammation and have been tested for efficacy in the treatment of RA. Atorvastatin treatment resulted in a small reduction in RA disease activity
Mechanisms of RA pertinent to CV disease
Emerging evidence suggests that T lymphocytes play a crucial pathogenic role in both RA and heart disease.58, 59 The major risk gene for RA, HLA-DRB1, predisposes to disease by promoting the selection and survival of autoreactive CD4+ T cells. HLA-DRB1 alleles are also associated with increased risk of MI and various forms of non–RA-associated heart disease.60, 61 As in heart disease, T cells isolated from the joints of patients with RA have enhanced production of interferon-γ and
Conclusion
Heart disease remains a major problem for patients with RA. Systemic inflammation plays a major role, through direct and indirect effects on the vasculature (Figure 2). More research is needed to delineate the disease mechanisms and to develop and evaluate risk assessment tools, biomarkers, prevention strategies, and treatments that are specific to RA. The CV risk in patients with RA is not well recognized by practicing physicians, and better recognition and control of traditional risk factors
Disclosures
No extramural funding was used to support this work. The authors are solely responsible for the design and conduct of this work, the drafting and editing of the manuscript, and its final contents.
References (79)
- et al.
Outcomes in patients with rheumatoid arthritis and myocardial infarction
Am J Med
(2010) - et al.
Subclinical peripheral arterial disease in rheumatoid arthritis
Atherosclerosis
(2010) - et al.
Exercise training and cardiac rehabilitation in primary and secondary prevention of coronary heart disease
Mayo Clin Proc
(2009) - et al.
Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis
Am Heart J
(2009) - et al.
Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease
Am J Cardiol
(2011) Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)
J Thromb Haemost
(2009)- et al.
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial
Lancet
(2004) - et al.
Simvastatin improves endothelial function in patients with rheumatoid arthritis
J Am Coll Cardiol
(2005) - et al.
Proinflammatory HLA-DRB1*01-haplotype predisposes to ST-elevation myocardial infarction
Atherosclerosis
(2012) - et al.
A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease
J Am Coll Cardiol
(2007)
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Lancet
Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
Am Heart J
Patterns of cardiovascular risk in rheumatoid arthritis
Ann Rheum Dis
Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study
Arthritis Rheum
Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study
Arthritis Rheum
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis
Ann Rheum Dis
The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years
Arthritis Rheum
The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population
Arthritis Rheum
Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden
BMC Neurol
Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events?
Arthritis Rheum
Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations
Arthritis Rheum
Rheumatoid arthritis and macrovascular disease
Rheumatology
Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization
JAMA
Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease
Ann Rheum Dis
Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors
Curr Vasc Pharmacol
Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis
Arthritis Rheum
Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis
Arthritis Rheum
Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics
Arthritis Rheum
Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis
Rheumatology (Oxford)
Cardiovascular death in rheumatoid arthritis: a population-based study
Arthritis Rheum
Autoantibodies and the risk of cardiovascular events
J Rheumatol
Poor physical fitness and performance as predictors of mortality in normal populations and patients with rheumatic and other diseases
Clin Exp Rheumatol
Benefits of exercise in rheumatoid arthritis
J Aging Res
Effects of high-intensity resistance training in patients with rheumatoid arthritis: a randomized controlled trial
Arthritis Rheum
Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial
Arthritis Rheum
Effect of intensive exercise on patients with active rheumatoid arthritis: a randomised clinical trial
Ann Rheum Dis
Predictors of exercise and effects of exercise on symptoms, function, aerobic fitness, and disease outcomes of rheumatoid arthritis
Arthritis Rheum
Effects of a modified dance-based exercise on cardiorespiratory fitness, psychological state and health status of persons with rheumatoid arthritis
Am J Phys Med Rehabil
Preventive medical services among patients with rheumatoid arthritis
J Rheumatol
Cited by (0)
Ms Crowson has research funding from Pfizer and Roche/Genentech. Dr Liao is supported by National Institutes of Health (NIH) K08 AR060257 and Katherine Swan Ginsburg Fund. Dr Davis is a site primary investigator for industry-sponsored trials with UCB Pharma and Roche. Dr Solomon is supported by NIH K24 AR 055989; receives research support from Amgen, Lilly, and Abbott; serves as an epidemiologic consultant to CORRONA; and serves in unpaid roles on 2 Pfizer sponsored trials. Dr Matteson has research funding from Pfizer and is involved in an industry-sponsored trial with Roche/Genentech. Drs Knutson and Hlatky reported that they have no relationships relevant to the contents of this manuscript to disclose. Dr Hlatky is funded by the American Heart Association. Dr Gabriel is supported by NIH R01 AR46849, receives research support from Pfizer, and serves as a consultant for Roche/Genentech.